- Home
- LXEH vs ANL Comparison
LXEH vs ANL Comparison
Compare LXEH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEH | ANL |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | China | Cayman Islands |
| Employees | 192 | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 52.0M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LXEH | ANL |
|---|---|---|
| Price | $0.32 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 236.5K | 13.6K |
| Earning Date | 12-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $1.00 |
| 52 Week High | $50.08 | $2.99 |
Technical Indicators
Market Signals| Indicator | LXEH | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 23.81 |
| Support Level | $0.31 | $1.32 |
| Resistance Level | $0.37 | $1.59 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 18.36 | 1.69 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.